– Late-breaking results from global Phase 3 confirmatory studies of PADCEV (EV-302) in locally advanced or metastatic bladder cancer and TIVDAK (innovaTV 301) in recurrent or metastatic cervical ...
Experts highlight perioperative Padcev plus Keytruda in bladder cancer, showing potential practice-changing results from ESMO 2025 for patients. Following the 2025 European Society for Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results